Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fazirsiran in Alpha-1 Antitrypsin Deficiency
NCT03945292Phase 2Completed
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Aug 2019
- Primary completion
- Nov 2021
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of fazirsiran in alpha-1 antitrypsin deficiency (AATD) (4 arms), sponsored by Arrowhead Pharmaceuticals. Primary endpoint: Percent Change From Baseline in Serum Z-Alpha-1 Antitrypsin at 16 weeks. Started Aug 2019; status: completed.
02
Drugs
fazirsiran
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on NCT03945292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03945292.